ArticleBMC gastroenterology2026
Comparative safety and efficacy of hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy, with or without transarterial chemoembolization, in unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInterventional therapies and systemic chemotherapy are the mainstay of treatment for patients with unresectable hepatocellular carcinoma (HCC). This study aimed to generate preliminary evidence regarding the feasibility and safety of transarterial chemoembolization (TACE) combined with hepatic artery infusion chemotherapy (HAIC), targeted therapy, and immunotherapy in patients with unresectable hepatocellular carcinoma (HCC).
methodsThis retrospective study analyzed 213 patients with unresectable HCC treated with TACE plus HAIC, targeted therapy, and immunotherapy (THTI) or HAIC plus targeted therapy and immunotherapy (HTI) between July 2019 and August 2023. Propensity score matching (PSM) was used to balance potential confounders between patients in the THTI and HTI groups. Overall survival (OS) was assessed using Kaplan-Meier analysis, and the log-rank test was used for between-group comparisons. Cox proportional hazards regression models were used to identify independent influences on patient OS.
resultsA total of 213 patients were treated with THTI (n = 41) or HTI (n = 172). After 1:2 PSM, there were 31 patients in the THTI and 62 patients in the HTI groups. After PSM, OS was significantly better in the THTI than in the HTI groups (34.4 vs. 16.3 months, P = 0.013). The objective response rate (ORR) (38.71% vs. 45.16%, P = 0.554) and disease control rate (DCR) (80.65% vs. 79.03%, P = 0.856) were not statistically significant in the THTI and HTI groups. THTI treatment is an independent predictor of OS. All adverse events (AEs) in the THTI and HTI groups were manageable.
conclusionCompared with HTI, THTI was associated with improved OS in patients with unresectable HCC, with manageable short-term AEs. Quadruple therapy showed encouraging antitumor activity in this retrospective cohort and should be considered exploratory, further large-scale prospective studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.